- Open Access
Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
- Zhen Jin†1,
- Kai Qing†1,
- Yuan Ouyang1,
- Zhao Liu2,
- Wenfang Wang1,
- Xiaoyang Li2,
- Zizhen Xu3Email author and
- Junmin Li2Email author
© Jin et al. 2016
- Received: 30 December 2015
- Accepted: 17 March 2016
- Published: 24 March 2016
Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes.
The synergetic effects were assessed by CCK-8 assay and measured by isobologram analysis. The NVP-Bez235 and lenalidomide cytotoxicity were measured by flow cytometry, Western Blot and si-RNA transfection. The combined treatment inducing tumor regression in vivo was performed in nude mice of OCI-Ly10 xenograft mouse model.
Low dose of two agents represented significant inhibition of proliferation with CI value < 1. NVP-Bez235 combined with lenalidomide remarkably increased apoptosis through intrinsic pathway by upregulating Bim, Bax and downregulating Bcl-xL. Akt, especially NF-κB, played an important role in the synergetic effects. Cotreatment also induced the cell cycle to be arrested in G0/G1 phase, and decreased S phase by increasing p21 expression, downregulating cyclinA and diminishing CDK2 phosphorylation in Su-DHL2 and OCI-Ly3 but not in OCI-Ly10. Mice treated with NVP-Bez235/lenalidomide represented obvious tumor growth regression and prolonged overall survival.
Our findings demonstrated the synergistic effect of low dose of NVP-Bez235 and lenalidomide in ABC-DLBCL, the underlying mechanism may be multifunctional, involving apoptosis, Akt and NF-κB inactivation and cell cycle arrest. Cotreatment was also effective in vivo. These data pave the way for potential treatment of ABC-DLBCL with combination of NVP-Bez235 and lenalidomide.
- Diffuse large B cell lymphoma
- PI3K/mTOR inhibitor
- Cell cycle
DLBCL is the most common B-cell non-Hodgkin’s lymphoma (NHL), accounting for about 30–35 % of adults NHL cases . Nearly up to one-third patients suffered from relapsed and refractory disease after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) treatment , and limited patients got benefits from the salvage strategy of autologous stem cell transplantation (ASCT), indicating new agents are required to be tested in this group of people.
However, the heterogeneity made DLBCL a complex disease to handle with. DLBCL is considered to be characterize into three major subtypes with distinct activating molecular pathways and different clinical outcomes based on the gene expression profiling results . Patients with activated B cell-like (ABC) subtype, characterised as constitutive NF-κB activation, were considered to have lower progression free survival (PFS) rate and overall survival (OS) rate compared with those with germinal center B-cell (GCB) subtype or primary mediastinal B-cell lymphoma (PMBL) . Regarding of the participation of NF-κB in many cell processes like tumor proliferation, invasion and inflammation, targeting NF-κB pathway has become one of the promising therapeutic approach in ABC-DLBCL treatment . Directly interrupting NF-κB pathway is one option of therapeutic strategy, and lenalidomide, which is used as the immunomodulatory agent treating multiple myeloma (MM), was proved to have anti-tumor effects through downregulating IRF-4 in ABC-DLBCL cell lines . The selective anti-tumor effect of lenalidomide in DLBCL is also supported by clinical studies. Increasing evidence revealed that ABC-DLBCL patients got better response with higher remission rate and PFS rate when treated with lenalidomide alone or combination with R-CHOP regime [7, 8]. Meanwhile, lenalidomide was found to have inhibiting function of tumor growth through PI3K/Akt pathway, cereblon/p21, cyclin D1/p27 and Bcl-2 in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) in pre-clinical experiments [9–13]. Besides, it also showed effeciency when combined with rituximab, dexamethasone and bortezomib in clinical trials of treating several types of B-cell NHL [14, 15], which implied the potential combination with other agents in lymphoid hematological maliganancies.
Indirectly, interrupting the upstream of NF-κB could also induce the inhibition of NF-κB pathway. It is known that the constitutive NF-κB activation in ABC-DLBCL is caused by individual or overlapping known mutations like MYD88 L265P, CARD11, TNFAIP3 and CD79B/A , which are involved in antigen-specific B-cell receptor (BCR) and Toll-like receptor (TLR) induced NF-κB activation. In the signaling cascade triggered by BCR, several tyrosine kinases including PI3K, Bruton tyrosine kinase (BTK) and mTOR are participated in, subsequently inducing the downstream pathways associated with survival. NVP-Bez235 is one of the dual PI3K/mTOR inhibitors that can suppress the activity of PI3K, mTOR1 and mTOR2. It has shown anti-tumor activity in a range of hematological malignancies including MM, MCL, follicular lymphoma (FL), chronic lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML) in the pre-clinical studies [17–21]. It was also reported to synergize with agents such as MEK1/2 inhibitor . Inhibition of mTOR could consequently decrease the phosphorylation of P70S6 kinase as well as eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), while PI3K activity represented an inexplicit relationship with mTOR in the complex cell signaling circuits.
Collectively, the findings make us to explore the efficacy of combined lenalidomide with NVP-Bez235 in treating ABC-DLBCL in vitro and in vivo. The aim of the present study was to determine whether lenalidomide could enhance the cytotoxic potency of NVP-Bez235 in ABC subtype of DLBCL, and to further elucidate the underlying mechanisms involved in this effect.
Cells and cell culture
The non-GCB DLBCL derived cell lines OCI-Ly10, OCI-Ly3 and Su-DHL2 were obtained from Dr. T Zhao (Nanfang Hospital affiliated to Southern Medical University, China). Cell lines were cultured in IMDM (Invitrogen, Carlsbad, USA) with 10 % FBS (Invitrogen, Carlsbad, USA), incubating in 37 °C with 5 % CO2.
Cell apoptosis was determined by flow cytometry according to the protocol of FITC Annexin V Apoptosis Detection Kit I (BD Bioscience, SanJose, CA, USA). Cells were collected and washed by cold phosphoate-buffered saline (PBS), then resuspended in Annexi-binding buffer and sustained with propidium iodide (PI) and FITC Annexin V. After incubating in the dark at room temperature for 15 min, cell suspensions were diluted by Annexin-binding buffer and analysed by BD LSRFotessa flow cytometry (SanJose, CA, USA) immediately. Data were acquired by BD FACSDiva software (SanJose, CA, USA).
Cell proliferation assays
Analysis of cell proliferation was performed with cell counting kit-8 (Dojindo, Japan) assay. NVP-Bez235 and lenalidomide were purchased from Selleck (Huston, USA) and dissolved in DMSO. The treatment of BEZ235 was performed as 5nM, 10nM, 20nM and 40nM, while the working concentration of lenalidomide were 0.5 μM, 1 μM, 2 μM and 4 μM. Cells were seeded in 96-well plate at a concentration of 1 × 105/mL. After 72 h, 10uL cell counting kit-8 were added to each well and incubated for 2 h. The absorbance at 450 nm was measured by a microplate reader. Growth inhibition was calculated by the formula (O.D absorbance of treatment group – O.D absorbance of blank)/(O.D absorbance of control group – O.D absorbance of blank) × 100 %. The synergetic effect of two drugs was measured by combination index (CI) using CalcuSyn software (Version 2.1). CI < 1 indicates the synergetic effect, CI = 1 means the additive effect and CI > 1 is regarded as antagonism.
NF-κB Pathway Sampler Kit, Akt, p-Akt (Ser 308), p-Akt (Thr 473), p21, p-CDK2, CDK2, cyclinA, cyclinD1, mTOR Pathway Sampler Kit, and Apoptosis sampler Kit were obtained from Cell Signaling Technology (Beverly, MA, USA). All the cell lines were treated with NVP-Bez235 and lenalidomide in single way or combination for 72 h. Bortezomib was purchased from Selleck (Huston, USA). Cells were performed with 5 nM Bortezomibe for 24 and 48 h, respectively. Then the samples in each group were collected and separated by standard SDS-PAGE gel electrophoresis and transferred to NC membrane. Blocked with 5 % non-fat milk supplemented in 0.1 % TBST, membrane was probed with primary antibodies at 4 °C overnight. After washed with TBST, membrane was incubated with HRP-conjugated secondary antibodies (Santa Cruz, CA) for one hour. The bands were detected and quantified in Image Lab software (Bio-Rad Laboratories, California, USA).
Gene silencing with siRNA
NF-κB siRNA were purchased from Santa Cruz (CA, USA). Non-silencing siRNA was designed and synthesized as following: sense 5′-UUCUCCGAACGUGUCACGUTT-3′, antisense 5′-ACGUGACACGUUCGGAGAATT-3′. Cell lines were transiently transfected NF-κB siRNA and non-silencing siRNA by using LipofectAMINE2000 reagent (Invitrogen, Carlsbad, CA). After incubated for 8 h, lipid containing siRNA was removed and warmed complete medium was added. Cells were cotreated with NVP-Bez235 and lenalidomide for another 48 h following 24-h-transfection. Cells were collected for immunoblotting. Cell viability was measured when cells were transfected for 24 h followed with 48 h.
Cell cycle assay
Each cell line was seeded in a 12-well plate exposing in drugs for 72 h. Then the cells were collected, centrifuged, washed with ice-cold PBS and resuspended with 70 % alcohol. After fixed in -20 °C for 12 h, the cells were washed and stained with PI and ribonuclease A (Beytime Instituted of Biotechnology, China) at room temperature for 30 min. Cell cycle data were assessed by BD LSRFortes flow cytometry (SanJose, CA, USA) and analyzed by Modfit LT 4.1 (Verity Software House, Topsham, USA).
Six-weeks old nude female mice, purchased from Shanghai Laboratory Animal Center (Shanghai, China), were injected subcutaneously in the right flank with 1 × 107 OCI-Ly10 cells in 100 μL saline. When the tumor volume reached to about 150–300 mm3, mice were randomly divided into 4 groups with 5 mice per group as follows: (I) control: intraperitoneally injected with saline; (II) NVP-Bez235: Bez235 20 mg/kg by oral gavage,dissoved in 10 % NMP (1-methyl-2-pyrrolidone)/PEG 300 90 %, every other day; (III) lenalidomide: intraperitoneally injected lenalidomide 10 mg/kg/day (diluted in 4 % DMSO, 96 % saline); (IV) combination: treatment of NVP-Bez235 with lenalidomide. The tumor volumes were measured every other day by vernier caliper for 28 days and calculated as V = a × b2/2(a, the length of tumor; b, the width of tumor). At the end of observation, mice were killed to remove the tumors. Then the samples were fixed in 4 % formalin and further performed to frozen section. Animal protocol was approved by the Animal Care and Use Committee of Ruijin Hospital affiliated to School of Medicine, Shanghai Jiao Tong University.
Fixed slides obtained from samples of nude mice were incubated in 3 % H2O2 for 10 min to suppress endogenous peroxidase activity and then washed in PBS. Next, the slides were blocked with 1.5 % serum in PBS at room temperature for 30 min and subsequently in BSA for 20 min. Then the slides were incubated with primary antibodies p-NF-κB and Ki-67 (Santa Cruz, CA, USA) overnight. After washed for 15 min, the slides were added with secondary antibodies connected with biotin for half an hour and incubated with SABC (Boster, Wuhan, China). After incubating with a solution of DAB (Boster, Wuhan, China), the tissue slides must be checked under microscope to get appropriate staining. The final steps were counterstaining, dehydrating, clearing and mounting. The positive cells were counted using Image-Pro plus 6.0 (Media Cybernetics, USA).
Terminal deoxytransferase-catalyzed DNA nick-end labeling (Tunel) assay
Frozen sections were performed with a terminal transferase recombinant kit (Roche, Indianapolis, IN, USA) under the guidelines of production information. Cells with green fluorescence were termed as the apoptosis section. Image-Pro plus 6.0 (Media Cybernetics, USA) were used to analyze the positive cells in each slide.
All data in this study were analyzed with SPSS 17.0 software (Chicago, USA) and presented as mean ± standard deviation. Independent t test were used to determine the significance of difference between groups. IC50 value was analyzed by probit assay in SPSS. P < 0.05 was considered as statistically significance Overall survival was measured by Kaplan-Meier method. The drug interactions were stated according to Chou-Talalay method and isobologram analysis.
Growth suppression of NVP-Bez235 and lenalidomide in ABC subtype of DLBCL cell lines
IC50 values of Bez235 (5-40nM) in ABC- DLBCL cell lines for 72 h
CI 95 %
CI 95 %
CI 95 %
Low dose of lenalidomide and NVP-Bez235 displays synergistic effect on ABC-DLBCL cell lines in vitro
Isobologram analysis of NVP-Bez235 in combination with lenalidomide
Combination of NVP-Bez235 and lenalidomide promote the apoptosis through caspase activation and Bcl-2 family regulation
As the pivotal role of Bcl-2 family in the apoptosis intrinsic pathway, pro-apoptosis members (Bax, Bad, Bim) and anti-apopotosis members (Bcl-2 and Bcl-xL) were selected to determine the disturbance induced by single drug treatment or agents combination. Bim-EL and Bim-S were elevated remarkably by drug combination in all cell lines (Fig. 2d). The level of Bax was obviously upregulated by drug combination especially in Su-DHL2. However, we did not observe upregulation of p-Bad to a greater extent in combination group compared with NVP-Bez235 group. Among the anti-apoptosis molecules, Bcl-xL was remarkably downregulated by drug combination. Unlikely, Bcl-2 varied among cell lines. Agent combination induced Bcl-2 downregulation in Su-DHL2, upregulation in OCI-Ly3 and moderate change in OCI-Ly10. The results indicated that apoptosis trigged by drug combination was primarily mediated by intrinsic apoptosis pathway, of which the pro-apoptosis members overwhelmed the anti-apoptosis members.
Akt and NF-κB pathway contribute to growth inhibition induced by drug combination
NVP-Bez235 and lenalidomide combination arrested cell-cycle in G0/G1 phase
Cotreatment of NVP-Bez235 and lenalidomide inhibit the mTOR pathway in vitro
Combined low dose of NVP-Bez235 and lenalidomide suppressed tumor growth and prolonged the overall survival of the xenograft model of DLBCL
To confirm our studies of growth suppression mechanism, immunohistochemical analysis was conducted to identify the expression of Ki67 and p-NF-κB in each cohort. Combined treatment reduced the positive cells of Ki67 compared with control group (p < 0.01) and NVP-Bez235 group (p = 0.005) (Fig. 7d). While it seemed that lenalidomide moderately enhanced tumor suppression induced by NVP-Bez235 according to the comparison of Ki67 expression with NVP-Bez235 and cotreatment group (p = 0.04 < 0.05). Cotreatment of NVP-Bez235/lenalidomide also increased the apoptosis (p < 0.001), revealed by Tunnel assay (Fig. 7f), which matched our previous studies in vitro. Although the positive cells stained with p-NF-κB were obviously reduced by NVP-Bez235 (p < 0.001), the drug combination did not enhance repression compared with the NVP-Bez235 group to a greater extent (p = 0.023 < 0.05) (Fig. 7e), which is not as effective as it did in vitro. Our results suggested that NVP-Bez235 combined with lenalidomide could remarkably delay the tumor growth by inducing apoptosis and inhibiting proliferation in vivo, but the mechanism of this suppression may be caused by multiple pathways including downregulation of p-NF-κB.
Combination strategy has represented lower toxicities and overcoming agent resistance in treatment of DLBCL. The oncogenetic molecular mechanisms involved in ABC-DLBCL were primarily initiated by BCR subunit activated mutations, as well as the CARD11 and MYD88 mutations, resulting in the constitutive activation of NF-κB [16, 24]. Meanwhile, constitutive PI3K signaling activation, resulted from the chronic BCR activation, was proved to support the viability of ABC-DLBCL . For this reason, targeting proteins involved in these pathways is a rationale way in treating ABC-DLBCL. NVP-Bez235, a dual mTOR/PI3K inhibitor, was found to synergistically interact with BTK inhibitor Ibrutinib  and HDAC inhibitors . In our study, we demonstrated that combination of low dose of NVP-Bez235 and lenalidomide played synergistic roles in killing ABC-DLBCL cells.
ABC-DLBCL cell lines showed different sensitivity to NVP-Bez235 and lenalidomide. Su-DHL2 and OCI-Ly3 were more vulnerable to single agent, but OCI-Ly10 showed a little resistant. Investigations of the direct cytotoxicity of lenalidmide in DLBCL [6, 28] have supported our findings. This difference also resulted in the variety in antiproliferation of combination treatment with different doses. The antagonistic effect appeared when drug doses escalated to higher level in all cell lines. Importantly, the synergistic effect was maintained when the concentrations of both drugs were well below clinical Cmax [23, 29]. It was reported that NVP-Bez235 has no toxicity in normal CD34+ hematopoietic cells , and lenalidomide has limited long-term toxicity , suggesting the potential clinical application value of this combination strategy. We then examined the apoptosis induced by drug combination, and the results are in accordance with our previous findings. The apoptosis proportion of OCI-Ly10 was not as much as those of Su-DHL2 and OCI-Ly3. The difference of toxicity may be explained, at least partly, with the heterogeneity of DLBCL. OCI-Ly3 and OCI-Ly10 both maintain the MYD88-L256P mutation while Su-DHL2 gets the mutation of MYD88-S222R . Meanwhile, mutation of CARD11, which induces the activation of IKK2 and NF-κB, also existed in OCI-Ly3 but not in OCI-Ly10 , and mutation of TNFAIP3/A20 was observed in Su-DHL2 . Collectively, the various mutation statues in each cell lines may be the underlying reasons of the various responses to single agent treatment or drug combination. In order to explain the different toxicity responses, we further examined the intrinsic pathway and extrinsic pathway, and found that apoptosis intrinsic pathway played a predominant role in the synergistic effect. To date, the complex process of apoptosis could be mainly categorized into intrinsic and extrinsic pathway, finally resulting in the DNA fragmentation and cell death. Stimulations from extracellular activated the transmembrane receptor and consequently triggered the activation of extrinsic initiator of caspase 8. In contrast, intrinsic pathway was initiated by mitochondrial events and resulted in the activation of caspase 9 through a more complex procedure. Finally, both extrinsic and intrinsic pathways would go through the execution pathway, which is considered as the end point of apoptosis. Caspase 3 is regarded as the most essential effector in the apoptosis execution pathway. Once it is activated by caspase 8 or caspase 9, the activated caspase 3 will further induce the cleavage of various subtracts such as PARP, which is a nuclear DNA-binding protein functioning as DNA breaks detector. The mitochondrial events of intrinsic pathway taken place in and controlled by Bcl-2 family, which can group into proapoptotic members and antiapoptotic members. At the initiation, Bim plays a crucial role . Subsequently, oligomerization of Bak and Bax permeabiliaze the mitochondrial membrane and release SMAC and cytochrome c, further activating caspase9 and finally inducing apoptosis. The Bim up-regulation was required in the synergy of lenalidomide and NPI-0052 in MM , as well as in the contributing effect of NVP-Bez235 and HDAC inhibitor in DLBCL . Here our results also showed that combined NVP-Bez235 and lenalidomide resulted in the accumulation of Bim-S, Bim-EL isoforms and Bax. Bad, a member of BH3-only protein, was regarded to exhibit the proapoptosis functions by directly binding and inhibiting anti-apoptotic member Bcl-2 and was reported to be associated with the DBLCL tumorigenesis . We did not find stronger phosphorylation of p-Bad in the combination treatment, suggesting other members may exert more important efforts in the apoptosis. We next identified the dysregulation of anti-apoptotic members including Bcl-2 and Bcl-xL. The Bcl-xL expression was significantly reduced by drug combination. However, the Bcl-2 expression varied among the cell lines. One reason may partly explain the chaos of Bcl-2. The oncogenic function of Bcl-2 was first reported as its overexpression could promote the c-myc driven proliferation . Patients who suffered with the “double-hit” DLBCL, representing the translocation of MYC with the arrangements of BCL2, BCL6 or CCND1, often turn out to be with poor prognosis . C-MYC amplification was found in OCI-Ly3 but not in OCI-Ly10 , and there was no report on the C-MYC status in Su-DHL2. These led us to assume that the diverse of MYC expression in cell lines causes the Bcl-2 variation in different cell lines. We did not examine the change of anti-apoptotic member Mcl-1 induced by drug combination. To our knowledge, Mcl-1 was elevated in ABC-DLBCL , and many pre-clinical studies have reported its necessity in drug-induced apoptosis of DLBCL [27, 39, 40]. Altogether, our results demonstrated that the drug combination induced the apoptosis through the intrinsic pathway by elevating the cleaved-caspase 9, Bim and Bax, as well as downregulating the expression of Bcl-xL.
The mechanism involved in the synergetic effect was further depicted by examination of Akt and NF-κB pathway. Since lenalidomide was reported to exert its immunomodulatory function through PI3K/Akt pathway in CLL , we found that lenalidomide only slightly dephosphorylated p-Akt (Ser 473) in OCI-Ly10 and p-Akt (Thr 308) in Su-DHL2, which in line with the study of lenalidomide cytotoxicity in MCL . Robust downregulation of p-Akt (Ser 473) and p-Akt (Thr 308) was observed in Su-DHL2 and OCI-ly3 by co-treatment, indicating the importance of PI3K/Akt in the synergetic effect. The activation of NF-κB was well considered to support the viability of ABC-DLBCL. Recurrent somatic mutations resulted in the activity of NF-κB varied among cell lines, of which MYD88-L256P got higher NF-κB activity than MYD88-S222R . Specifically, the expression of NF-κB, p-p65 and p52 was predicted to be a poor prognosis factor of DLBCL in some studies [42, 43], as well as the p-IΚBα in ABC-DLBCL , but the expression of Rel was reported to be associated with superior clinical outcome . Tracing the validation of NF-κB pathway in prognosis, function of NF-κB was estimated to cooperate with FOXP1 and BLIMP1 in ABC-DLBCL [46, 47]. Abundant researches indicated that NF-κB monitored the cell life and death through regulating apoptosis program in a caspase-independent way . Regarded as an anti-apoptosis transcription factor, NF-κB could induce a number of gene expressions, of which the production acts as the apoptosis inhibitor. C-IAPs and c-FLIP are well established NF-κB-regulated proteins. Besides, NF-κB was also found to modulate the Bcl-2 family and pro-/anti-apoptosis pathways through TRAF1 and TRAP2 . Owing to the important role of NF-κB in cell fate, members involved in the NF-κB pathway were further detected. We found that NVP-Bez235 and lenalidomide treatment also substantially downregulated NF-κB pathway. However, we did not assess whether suppression of Akt activity was involved in the regulation of NF-κB, but it seemed that PI3K could only directly affect high level of nuclear NF-κB in DLBCL cell lines . In contrast, other studies indicated that NF-κB was controlled by PI3K [50, 51]. In addition, as NVP-Bez235 also inhibited the mTOR pathway, whether NF-κB is independent with mTOR pathway requires further study. Of note, our confirmation of the role of NF-κB in synergetic effect also implied that the mechanism could not be simply explained by the inhibition of Akt and NF-κB pathways, so there must be other biological impacts contributing to this effect.
Cell cycle arrest has been observed in the anti-NHL and anti-CLL activity of PI3K inhibitor as well as lenalidomide [12, 41, 52–54]. In our study, sharp decrease of S phase was observed in Su-DHL2 and OCI-Ly3 cell lines with apparently increase of G0/G1 phase after exposed in both NVP-Bez235 and lenalidomide, suggesting the cell cycle arrest contributed to the combined cytotoxicity. Furthermore, in view of importance of CDK2/cyclinA in G1/S phase transition , abrogation of cyclinA and dephosphorylation of p-CDK2 in Su-DHL2 and OCI-Ly3 by cotreatment may contribute to the ultimate cell death. Indeed, deregulation of CDK2 and CDK4 genes has been found to be associated with the transformation process of the transformed DLBCL , additionally, CDKN2A deletion was predicted for poor prognosis in DLBCL , suggesting the important role of CDK2 in pathogenesis of DLBCL. It was known that p21 and p27 normally arrest cell cycle by suppressing the activity of CDKs, but we did not examine the expression of p27. p21 could be upregulated by lenalidomide , which is in line with our studies, and was even associated with prognosis, for example, p53 + p27 + p21-p16- and low p27 expression was suggested with poor clinical outcomes and shorter survivals [58, 59]. CyclinD1 was accumulated by NVP-Bez235/lenalidomide cotreatment, which is in contrast with the results of lenalidomide in MCL . The overexpression of cyclinD1 in DLBCL, accounting for 1.5–15 % [60–62], showed no prognosis value , indicating the cyclinD1 may not be as important as cyclinA/CDK2. The mechanism by which Akt or NF-κB inhibition diminish cyclinA or p-CDK2 in our study is unclear, but Chiron et al reported that PI3K inhibitors induced cell cycle arrest by downregulating CDK4/6 , and NF-κB was reported to be associated with cell cycle regulation .
Finally, our in vivo studies demonstrated that concomitant treatment of NVP-Bez235 and lenalidomide exerted potential antitumor activitity with well tolerant doses. Specifically, although lenalidomide single treatment did not show anti-DLBCL activity in vivo, it significantly enhanced NVP-Bez235 antitumor potency by delaying the tumor growth and prolonging the overall survival. Moreover, the apoptosis and growth inhibition with cotreatment in vitro could also be detected in tumor tissues. Unlikely, NVP-Bez235/lenalidomide cotreatment did not inhibit the phosphorylation of p-NF-κB to a great extent as it did in in vitro studies, suggesting that the mechanism of antitumor activity in intact animals may be more complex than the mechanisms in vitro.
Collectively, our study demonstrated that NVP-Bez235 combined with lenalidomide effectively inhibited cell proliferation, induced apoptosis and cell cycle arrest in ABC-DLBCL cell lines. Moreover, it was also active in the DLBCL xenograft model. The present findings also suggest that the mechanisms are likely associated with regulation of Akt and NF-κB pathway, inducing the apoptosis through upregulation of Bim, Bax and downregulation of Bcl-xL in all cell lines. Lenalidomide did not enhance the potency of NVP-Bez235 in OCI-Ly10 by inhibiting G1/S transition withincreasing p21 expression, downregulating cyclinA and dephophorylating p-CDK2. Notably, NF-κB may also be related to the drug resistance of DLBCL . Therefore, our present studies raise the possibility of a novel strategy to treat ABC-DLBCL patients by using the combination of NVP-Bez235 and lenalidomide.
This work was partly supported by National Natural Sciences Foundation of China (81270621) and the Natural Science Foundation of Shanghai (14ZR1425900).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63:11–30.Google Scholar
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23:4117–26.View ArticleGoogle Scholar
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.View ArticlePubMedGoogle Scholar
- Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.View ArticlePubMedGoogle Scholar
- Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33:251–7.View ArticleGoogle Scholar
- Zhang L-H, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502.View ArticlePubMedGoogle Scholar
- Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–66.View ArticlePubMedGoogle Scholar
- Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. Official Journal Of The American Society Of Clinical Oncology: Journal Of Clinical Oncology; 2014.Google Scholar
- Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553–9.View ArticlePubMedGoogle Scholar
- Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010;115:2619–29.View ArticlePubMedPubMed CentralGoogle Scholar
- Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117:4323–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124:1637–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martinez A, Colomer D, et al. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:393–403.View ArticleGoogle Scholar
- Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer. 2014;120:222–8.View ArticlePubMedGoogle Scholar
- James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014;32:2067–73.View ArticleGoogle Scholar
- Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–9.View ArticlePubMedGoogle Scholar
- Sandhofer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiss V, et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015;29:828–38.View ArticlePubMedGoogle Scholar
- Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2015;94:343–54.View ArticlePubMedGoogle Scholar
- Wong J, Welschinger R, Hewson J, Bradstock KF, Bendall LJ. Efficacy of dual PI-3 K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia. Oncotarget. 2014;5:10460–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosich L, Montraveta A, Xargay-Torrent S, Lopez-Guerra M, Roldan J, Aymerich M, et al. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget. 2014;5:6788–800.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010;24:1781–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. Journal of experimental & clinical cancer research: CR. 2014;33:52.View ArticlePubMed CentralGoogle Scholar
- Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–75.View ArticlePubMedGoogle Scholar
- Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (New York, NY). 2008;319:1676–9.View ArticleGoogle Scholar
- Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2011;108:272–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111:2349–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:4849–60.View ArticleGoogle Scholar
- Yang Y, Shaffer 3rd AL, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2011;29:3066.Google Scholar
- Usnarska-Zubkiewicz L, Debski J, Butrym A, Legiec W, Hus M, Dmoszynska A, et al. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients-Report of the Polish Myeloma Group. Leuk Res. 2015.Google Scholar
- Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Weber K, Harper N, Schwabe J, Cohen GM. BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. Cell reports. 2013;5:409–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010;115:834–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Ranger AM, Zha J, Harada H, Datta SR, Danial NN, Gilmore AP, et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9324–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–2.View ArticlePubMedGoogle Scholar
- Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A et al. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-celllymphoma patients treated with rituximab-CHOP. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015; 28:1555-1573.Google Scholar
- Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21:113–22.View ArticleGoogle Scholar
- Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 2013;27:1381–90.View ArticlePubMedGoogle Scholar
- Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17.PubMedGoogle Scholar
- Zang C, Eucker J, Liu H, Muller A, Possinger K, Scholz CW. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett. 2013;339:288–97.View ArticlePubMedGoogle Scholar
- Cosenza M, Civallero M, Pozzi S, Marcheselli L, Bari A, Sacchi S. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. Hematol Oncol. 2014.Google Scholar
- Zhao Q, Fu W, Jiang H, Du J, Zhang C, Xi H, et al. Clinicopathological implications of nuclear factor kappaB signal pathway activation in diffuse large B-cell lymphoma. Hum Pathol. 2015;46:524–31.View ArticlePubMedGoogle Scholar
- Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol. 2011;224:355–66.View ArticlePubMedGoogle Scholar
- Hussain AR, Uddin S, Ahmed M, Al-Dayel F, Bavi PP, Al-Kuraya KS. Phosphorylated IkappaBalpha predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PLoS One. 2013;8, e60540.View ArticlePubMedPubMed CentralGoogle Scholar
- Odqvist L, Montes-Moreno S, Sanchez-Pacheco RE, Young KH, Martin-Sanchez E, Cereceda L, et al. NFkappaB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27:1331–7.View ArticleGoogle Scholar
- Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18:580–9.View ArticlePubMedPubMed CentralGoogle Scholar
- van Keimpema M, Gruneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells. Blood. 2014;124:3431–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6910–24.View ArticlePubMedGoogle Scholar
- Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221–7.View ArticlePubMedGoogle Scholar
- Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer. 2010;9:97.View ArticlePubMedPubMed CentralGoogle Scholar
- Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One. 2012;7, e39945.View ArticlePubMedPubMed CentralGoogle Scholar
- Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011;35:380–6.View ArticlePubMedGoogle Scholar
- Gopalakrishnan R, Matta H, Tolani B, Triche Jr T, Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2015.Google Scholar
- Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer discovery. 2014;4:1022–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Sherr CJ. Cancer cell cycles. Science (New York, NY). 1996;274:1672–7.View ArticleGoogle Scholar
- Al-Assar O, Rees-Unwin KS, Menasce LP, Hough RE, Goepel JR, Hammond DW, et al. Transformed diffuse large B-cell lymphomas with gains of the discontinuous 12q12-14 amplicon display concurrent deregulation of CDK2, CDK4 and GADD153 genes. Br J Haematol. 2006;133:612–21.View ArticlePubMedGoogle Scholar
- Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116:1092–104.View ArticlePubMedGoogle Scholar
- Pasanen AK, Haapasaari KM, Peltonen J, Soini Y, Jantunen E, Bloigu R, et al. Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy. Eur J Haematol. 2013;91:29–36.View ArticlePubMedGoogle Scholar
- Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, et al. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2010;21:833–41.View ArticleGoogle Scholar
- Ehinger M, Linderoth J, Christensson B, Sander B, Cavallin-Stahl E. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. Am J Clin Pathol. 2008;129:630–8.View ArticlePubMedGoogle Scholar
- Hsiao SC, Cortada IR, Colomo L, Ye H, Liu H, Kuo SY, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology. 2012;61:685–93.PubMedGoogle Scholar
- Vela-Chavez T, Adam P, Kremer M, Bink K, Bacon CM, Menon G, et al. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leukemia & lymphoma. 2011;52:458–66.View ArticleGoogle Scholar
- Ok CY, Xu-Monette ZY, Tzankov A, O’Malley DP, Montes-Moreno S, Visco C, et al. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014;120:1818–29.View ArticlePubMedGoogle Scholar
- Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell cycle (Georgetown, Tex). 2013;12:1892–900.View ArticleGoogle Scholar
- Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73–90.View ArticlePubMedGoogle Scholar
- Turturro F. Constitutive NF- kappa B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma. BioMed research international. 2015;2015:484537.View ArticlePubMedPubMed CentralGoogle Scholar